Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
Methodological detailsDelphi procedure, international task force, Task force of 13 experts in rheumatology, epidemiology and pharmacology from seven European countries, Level of evidence (1a-5) and grade (A-D) determined per point; anonymous voting on level of agreement (0-10)
- Delphi procedure
- International task force
- Task force of 13 experts in rheumatology, epidemiology and pharmacology from seven European countries
- Level of evidence (1a-5) and grade (A-D) determined per point; anonymous voting on level of agreement (0-10)
Recommendations
As issued by the authors
Five overarching principles agreed
20 points to consider for 10 of 12 strategies: response prediction, drug formulary use, biosimilars, loading doses, low-dose initial therapy, concomitant csDMARD use, route of administration, medication adherence, disease activity-guided dose optimisation and non-medical drug switching
10 points to consider (50%) supported by level 1 or 2 evidence; mean level of agreement (LoA) (SD) between 7.9 (1.2) and 9.8 (0.4)
Original publication
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open. Published 2 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →